- Screening
- Preoperative indications
- Intraoperative indications
- Follow-up one week after aspiration
- Adverse events
- Follow-up 2
- Follow-up 3
- Management system of participants
- Speciman management system
- Data management system
- ADR/ADE management system
- Madicine management system
- Instruments management system
- SOPs
- Research team
- Design, Methods
|
Age ≥ 18 years old | |
|
Thyroid US indicates thyroid nodule. | |
|
US assessment accords with FNA criteria recommended by C-TIRADS | |
|
nodule with high insufficient rate | |
|
Informed consent |
|
Allergic to lidocaine or SonoVue | |
|
Refuse to CEUS | |
|
Severe abnormality of heart function or lung function | |
|
Severe abnormality of coagulation function | |
|
Pregnancy | |
|
Active infectious focus on cervical skin | |
|
Patients unable to cooperate for FNA or CEUS |
|
Registration number |
|
|
Birthday |
|
|
Sex | |
|
Telephone |
|
|
Date for signing informed consent |
|
|
Location of target thyroid nodule | |
|
transverse diameter | mm |
|
Anteroposterior diameter | mm |
|
Upper and lower diameter | mm |
|
Solid component (%) |
|
|
echo | |
|
edge | |
|
border | |
|
acoustic halo | |
|
Strong echo within nodule | |
|
Solid component of sheet-like strong echo (%) |
|
|
Score of ACR TI-RADS |
|
|
Rank of ACR TI-RADS |
|
|
Score of C-TIRADS |
|
|
Rank of C-TIRADS |
|
|
Ultrasonic diagnose |
|
|
VCs function evaluated by TLUSG | |
|
Routine blood test | |
|
Coagulation function |
- Time of aspiration
- Contrast-enhance indication (CEUS-FNA group)
- Progression of operation
- Intraoperative instant complication
|
Date of aspiration |
|
|
Start time |
|
|
End time |
|
|
Dosage of SonoVue |
|
|
No enhancement | |
|
Ratio of enhancement |
|
|
Injection of SonoVue during FNA |
|
Machine | |
|
Local anesthesia | |
|
other local anaesthesics |
|
|
Dosage of local anaesthesics | ml |
|
Patient compliance | |
|
Aspiration needle | |
|
FNA approach | |
|
Aspiration times |
|
|
Use of negative pressure | |
|
Pressure | ml |
|
Quality of nodule | |
|
Grittiness | |
|
Sample capacity |
|
Allergic to contrast agent | |
|
Painful | |
|
VAS score |
|
|
Analgesic | |
|
Painful when leave interventional room | |
|
Haemorrhage | |
|
Voice change | |
|
Vagal nerve syndrome | |
|
Horner syndrome | |
|
Aspiration related acute hypersensitivity reaction | |
|
location | |
|
visible for bleeding by CDFI | |
|
extend of hematoma (once after FNA) |
|
|
methods | |
|
visible hemorrhage by CDFI 30 minutes after FNA | |
|
extend of hematoma (before patient departure) | |
|
appearance | |
|
vocal cord mobility assessment by ultrasound | |
|
methods | |
|
whether the voice recovers when the patient leaves |
|
Pathological number |
|
|
Whether sample capacity is enough | |
|
Number of observable follicular epithelial cell clusters in specimen | |
|
Cytopathology classification |